Mohammad Shoari, M.D.
NPI 1740483395 · Specialist · Salt Lake City, UT
Enrolled with Medicare as Practitioner - Neurology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1740483395
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- Yes
- License
- 5761148-1205 (UT)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
798 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Needle Measurement of Electrical Activity in Arm Or Leg Muscles, Complete Study95886 | 373 | $88 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 154 | $121 |
| Nerve Conduction, 13 Or More Studies95913 | 84 | $262 |
| Nerve Conduction, 9-10 Studies95911 | 38 | $194 |
| Nerve Conduction, 11-12 Studies95912 | 38 | $227 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 41 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Gabapentin | 291 | 52 |
| Pregabalin | 101 | 21 |
| Donepezil Hcl | 96 | 26 |
| Lacosamide | 85 | 18 |
| Levetiracetam | 77 | 23 |
| Carbidopa/Levodopabrand: Carbidopa-Levodopa | 75 | 24 |
| Memantine Hcl | 71 | 18 |
| Lamotrigine |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$476 across 8 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-06-08
- Last updated
- 2007-07-08
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.